# BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

> **NCT00904839** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 128 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** BIBF 1120
- **DRUG:** BIBF 1120
- **DRUG:** mFolfox
- **DRUG:** Bevacizumab
- **DRUG:** mFolfox 6
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00904839
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2015-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00904839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00904839, "BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer". Retrieved via MORVS 2026-09-30 from https://api.morvs.ai/clinical/NCT00904839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*